Effects of bis(α-furancarboxylato)oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats

European Journal of Pharmacology

Volumn 572, Issue 2-3, 2007, Pages 213-219

  Niu, Yanfen ^a   Liu, Weiping ^b   Tian, Changfu ^a   Xie, Mingjin ^c   Gao, Lihui ^a   Chen, Zhihe ^a   Chen, Xizhu ^b   Li, Ling ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b KUNMING INSTITUTE OF PRECIOUS METALS   (China)

^c YUNNAN UNIVERSITY   (China)

Author keywords

Bis( furancarboxylato)oxovanadium(IV); Blood glucose; Fat fed streptozotocin rats; Glucokinase; Insulin; Phosphoenolpyruvate carboxykinase

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALLOXAN; ASPARTATE AMINOTRANSFERASE; BIS(ALPHA FURANCARBOXYLATO)OXOVANADIUM; CREATININE; GLUCOKINASE; GLUCOSE; OXALOACETIC ACID; PHOSPHOENOLPYRUVATE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PYRUVATE KINASE; STREPTOZOCIN; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE; VANADYL SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCOGEN LIVER LEVEL; HOMEOSTASIS; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; LIPID DIET; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIETARY FATS; GLUCOKINASE; GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY; LIVER; LIVER GLYCOGEN; MALE; ORGANOMETALLIC COMPOUNDS; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STREPTOZOCIN; VANADIUM;

EID: 34548740304     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.05.071     Document Type: Article

References (30)

1. Adachi Y., Yoshikawa Y., Yoshida J., Kodera Y., Katoh A., Takada J., and Sakurai H. Improvement of diabetes, obesity and hypertension in type 2 diabetic KKAy mice by bis(allixinato)oxovanadium(IV) complex. Biochem. Biophys. Res. Commun. 345 (2006) 945-950
2. Ahmad F., Considine R.V., Bauer T.L., Ohannesian J.P., Marco C.C., and Goldstein B.J. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J. Clin. Invest. 100 (1997) 449-458
3. Cai Z.F., Liu Q., Li P.P., Gao Z.R., and Shen Z.F. Synthesis and anti-diabetic activity of (RS)-2-ethoxy-3-{4-[2-(4-trifluoro-8methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid. Acta Pharmacol. Sin. 27 (2006) 597-602
4. Crans D.C., Smee J.J., Gaidamauskas E., and Yang L. The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds. Chem. Rev. 104 (2004) 849-902
5. Durbin D.J., Giese U.H., Guo H.H., and Radloff M. A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology 9 (2005) 3696-3701
6. Ferre T., Riu E., Bosch F., and Valera A. Evidence from transgenic mice that glucokinase is rate limiting for glucose utilization in the liver. FASEB J. 10 (1996) 1213-1218
7. Foster J.D., Pederson B.A., and Nordlie R.C. Glucose-6-phosphatase structure, regulation, and function: an update. Proc. Soc. Exp. Biol. Med. 215 (1997) 314-332
8. Futamura M., Hosaka H., Kadotani A., Shimazaki H., Sasaki K., Ohyama S., Nishimura T., Eiki J., and Nagata Y. An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J. Biol. Chem. 49 (2006) 37668-37674
9. Gao L.H., Liu W.P., Wang B.L., Li L., Xie M.J., Li Y.R., Chen Z.H., and Chen X.Z. Effects of bis(α-furancarboxylato)oxovanadium(IV) on non-diabetic and streptozotocin-diabetic rats. Clin. Chim. Acta 368 (2006) 173-178
10. Hanson R.W., and Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu. Rev. Biochem. 66 (1997) 581-611
11. Kraegen E.W., Clark P.W., Jenkins A.B., Daley E.A., Chisholm D.J., and Storlien L.H. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 40 (1991) 1397-1403
12. Marzban L., Rahimian R., Rrownsey R.W., and Mcneill J.H. Mechanisms by which bis (maltolato) oxovanadium (IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotoc in diabetic rats in vivo. Endocrinology 143 (2002) 4636-4645
13. Meyerovitch J., Rothenberg P., Shechter Y., Bonner-Weir S., and Kahn C.R. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J. Clin. Invest. 87 (1991) 1286-1294
14. Moller D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414 (2001) 821-827
15. Mosseri R., Waner T., Shefi M., Shafrir E., and Meyerovitch J. Gluconeogenesis in non-obese diabetic (NOD) mice: in vivo effects of vanadate treatment on hepatic glucose-6-phosphatase and phosphoenolpyruvate carboxykinase. Metabolism 49 (2000) 321-325
16. Nandan S.D., and Beale E.G. Regulation of phosphoenolpyruvate carboxykinase mRNA in mouse liver, kidney, and fat tissues by fasting, diabetes, and insulin. Lab. Anim. Sci. 42 (1992) 473-477
17. Niswender K.D., Postic C., Jetton T.L., Bennett B.D., Piston D.W., Efrat S., and Magnuson M.A. Cell-specific expression and regulation of a glucokinase gene locus transgene. J. Biol. Chem. 272 (1997) 22564-22569
18. Postic C., Shiota M., Niswender K.D., Jetton T.L., Chen Y., Moates J.M., Shelton K.D., Lindner J., Cherrington A.D., and Magnuson M.A. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic cell-specific gene knock-outs using Cre recombinase. J. Biol. Chem. 274 (1999) 305-315
19. Reed M.J., Meszaros K., Entes L.J., Claypool M.D., Pinkett J.G., Gadbois T.M., and Reaven G.M. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 11 (2000) 1390-1394
20. Rehder D. Biological and medical aspects of vanadium. Inorg. Chem. Commun. 6 (2003) 694-697
21. Scior T., Guevara-Garcia A., Bernard P., Do Q., Domeyer D., and Laufer S. Are vanadium compounds drugable? Structure and effects of antidiabetic vanadium compounds: a critical review. Mini Rev. Med. Chem. 5 (2005) 995-1008
22. Seely B.L., Staubs P.A., Reichart D.R., Berhanu P., Milarski K.L., Saltiel A.R., Kusari J., and Olefsky J.M. Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes 45 (1996) 1379-1385
23. 48V-labeled compounds in rats. J. Appl. Physiol. 2 (1998) 569-575
24. Shiota M., Postic C., Fujimoto Y., Jetton T.L., Dixon K., Pan D., Grimsby J., Grippo J.F., Magnuson M.A., and Cherrington A.D. Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes. Diabetes 50 (2001) 622-629
25. Srivastava A.K., and Mehdi M.Z. Insulino-mimetic and anti-diabetic effects of vanadium compounds. Diabet. Med. 22 (2004) 2-13
26. Van de Werve G., Lange A., Newgard C., Mechin M.C., Li Y., and Berteloot A. New lessons in the regulation of glucose metabolism taught by the glucose 6-phosphatase system. Eur. J. Biochem. 267 (2000) 1533-1549
27. Winter C.L., Lange J.S., Davis M.G., Gerwe G.S., Downs T.R., Peters K.G., and Kashibhatla B. A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats. Exp. Biol. Med. 230 (2005) 207-216
28. Xie M.J., Liu W.P., Li L., and Chen Z.H. Synthesis and anti-diabetic activity of bis(α-furancarboxylato)oxovanadium(IV). Acta Chimi. Sin. 60 (2002) 892-896
29. Xie M.J., Gao L.H., Li L., Liu W.P., and Yan S.P. A new orally active antidiabetic vanadyl complex - bis(α-furancarboxylato)oxovanadium(IV). J. Inorg. Biochem. 99 (2005) 546-551
30. Yuen V.G., Vera E., Battell M.L., Li W.M., and McNeill J.H. Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats. Diabetes Res. Clin. Pract. 43 (1999) 9-19